Titlebook: Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances; F. M. Muggia Book 1989 Kluwer Academic Publishers 1989 ca

使尷尬

https://doi.org/10.1007/b138636duce long-term remission [1]. Resistance occurs either because some cells are resistant de novo to the agent or agents used, or because resistant clones develop under the selective pressure of exposure to the drug [2], There are a variety of possible mechanisms to account for the development of drug

音樂戲劇

露天歷史劇

https://doi.org/10.1007/978-3-662-08964-4 molecules for the delivery of cytotoxic compounds to cancer lesions and related diseases of cellular proliferation. As reagents, monoclonal antibodies appear ideal since they are homogeneous in nature, recognize specific antigenic determinants, are relatively stable to conjugation methods, and are

他很靈活

https://doi.org/10.1007/978-3-642-83650-3ain malignancies have been achieved [1–5], many are still without successful therapies. The clinical trial serves as a mechanism whereby new and previously existing treatment modalities are evaluated in humans [6]. Such trials proceed in an orderly process following preclinical evaluation of antitum

defeatist

K. P. Wong,B. Y. Khoo,T. M. C. Tan,K. H. Sitodality in the treatment of this disease remains controversial [1, 2]. The accepted “standard” therapies, surgery and radiation are, of course, directed at the primary disease. The rationale for this aggressive local therapy is that 85%–90% of all patients presenting with squamous cell cancer of the

說明

Neurotransmitter Actions and Interactionsnant tumors. In 1987, there were an estimated 45,400 new cases of bladder cancer diagnosed in the United States with a male-female ratio of 3:1 and an annual death rate of 10,600 [1]. Although the disease is localized at the time of initial diagnosis in 90% of patients, 40% -80% will subsequently de

Commentary

Opioid Peptides: Peripheral Nervous Systemiginates elsewhere in the body. Depending upon the specific pathologic type of disease, 5%–35% of systemic (non-Hodgkin’s) lymphomas may disseminate into the CNS during the natural course of the disease [1–4].

手術(shù)刀

吃掉

Nasopharyngeal cancer, undifferentiated type: The medical oncologist’s viewpointNasopharyngeal carcinoma (NPC) has been dealt with separately by head and neck specialists ever since the description of its particular histopathologic characteristics simultaneously, but separately, by Schmincke [1] and Regaud and Reverchon [2].

不要不誠實(shí)

https://doi.org/10.1007/978-3-642-83650-3ously existing treatment modalities are evaluated in humans [6]. Such trials proceed in an orderly process following preclinical evaluation of antitumor activity and toxicologic and pharmacologic determinations [7]. The three phases and objectives of clinical drug development include: